Monte Rosa Therapeutics Inc (GLUE)

$5.85

-0.07

(-1.18%)

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Monte Rosa Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.4% return, outperforming this stock by 51.5%

Performance

  • $5.55
    $5.99
    $5.85
    downward going graph

    5.13%

    Downside

    Day's Volatility :7.27%

    Upside

    2.26%

    downward going graph
  • $2.44
    $8.84
    $5.85
    downward going graph

    58.29%

    Downside

    52 Weeks Volatility :72.4%

    Upside

    33.82%

    downward going graph

Returns

PeriodMonte Rosa Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
6.17%
-0.4%
0.0%
6 Months
113.5%
8.5%
0.0%
1 Year
-3.15%
4.2%
-1.2%
3 Years
-69.74%
13.9%
-19.2%

Highlights

Market Capitalization
296.9M
Book Value
$3.58
Earnings Per Share (EPS)
-2.63
Wall Street Target Price
16.83
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-27.72%
Return On Equity TTM
-60.07%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-137.1M
Diluted Eps TTM
-2.63
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.4
EPS Estimate Next Year
-2.26
EPS Estimate Current Quarter
-0.33
EPS Estimate Next Quarter
-0.64

Analyst Recommendation

Buy
    86%Buy
    13%Hold
    0
    0%Sell
Based on 15 Wall street analysts offering stock ratings for Monte Rosa Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 15 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
13
13
Hold
2
2
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 187.69%

Current $5.85
Target $16.83

Technicals Summary

Sell

Neutral

Buy

Monte Rosa Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics Inc
-21.48%
113.5%
-3.15%
-69.74%
-69.74%
Moderna, Inc.
Moderna, Inc.
-1.62%
26.13%
-28.15%
-35.32%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.25%
10.93%
12.37%
77.79%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-5.87%
27.44%
48.41%
234.91%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.33%
8.96%
19.79%
79.09%
133.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics Inc
1.25
NA
NA
-2.4
-0.6
-0.28
NA
3.58
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Monte Rosa Therapeutics Inc
Monte Rosa Therapeutics Inc
Buy
$296.9M
-69.74%
1.25
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
133.97%
28.33
36.68%

Institutional Holdings

  • NEA Management Company, LLC

    15.34%
  • FMR Inc

    11.04%
  • T. Rowe Price Associates, Inc.

    9.85%
  • Baker Bros Advisors LP

    9.80%
  • venBio Select Advisor LLC

    9.04%
  • BlackRock Inc

    4.73%

Company Information

small molecule protein degraders are set to reshape the way by which diseases will be treated. our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. headquartered in boston with additional laboratory facilities in basel, monte rosa therapeutics is a private company launched in 2020. initially seeded by versant ventures and incubated at ridgeline discovery in basel, and the institute of cancer research in london, monte rosa has raised $32.5 million from versant and new enterprise associates. academic co-founders are prof. raj chopra and prof. ian collins of the institute for cancer research, uk.

Organization
Monte Rosa Therapeutics Inc
Employees
133
CEO
Dr. Markus Warmuth M.D.
Industry
Services

FAQs